文献速递炎症性肠病

溃疡性结肠炎的临床病程:诊断后第一年生物制剂使用频繁且结肠切除率低——来自IBSEN III起始队列的结果

Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-04

IBSEN III是一项基于人群的前瞻性起始队列研究,纳入2017-2019年新诊断的877例成人溃疡性结肠炎患者,随访1年。诊断后1年内14.5%接受过至少一种生物制剂治疗,结肠切除率为0.9%,无激素临床缓解率76.6%,无激素内镜缓解率68.7%。

要点

  • 诊断后1年结肠切除率0.9%,无激素临床缓解率76.6%。
  • 1年内14.5%患者接受过至少一种生物制剂治疗。
  • 诊断时贫血和启动全身激素治疗与1年内使用生物制剂相关。

核心结论

  • 在该基于人群的起始队列中,诊断后第一年结肠切除率低,1年随访时高比例患者处于缓解。
  • 生物制剂使用增加,与既往研究结果一致。

研究设计与样本

  • IBSEN III研究为基于人群的起始队列研究,采用前瞻性随访。
  • 纳入2017-2019年新诊断的炎症性肠病患者,分析其中诊断时≥18岁且参加1年随访的溃疡性结肠炎患者。
  • 共纳入877例溃疡性结肠炎患者,中位年龄36岁(范围18-84岁),女性占45.8%。

主要发现

  • 诊断时直肠炎占39.2%,左半结肠炎占24.7%,广泛结肠炎占36.0%。
  • 1年随访时13.9%患者出现疾病进展,14.5%接受过一种或以上生物制剂治疗。
  • 结肠切除率为0.9%,无激素临床缓解率为76.6%,无激素内镜缓解率为68.7%。
  • 诊断时贫血和启动全身激素治疗与诊断后第一年内使用生物制剂相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of biologic therapies and the 'treat-to-target' treatment strategy may have changed the disease course of ulcerative colitis (UC). AIMS: To describe the early disease course and disease outcome at 1-year follow-up in a population-based inception cohort of adult patients with newly diagnosed UC. METHODS: The Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) III study is a population-based inception cohort study with prospective follow-up. Patients newly diagnosed with inflammatory bowel disease during 2017-2019 were included. Patients ≥18 years at diagnosis of UC who attended the 1-year follow-up were investigated. We registered clinical, endoscopic and demographic data at diagnosis and 1-year follow-up. RESULTS: We included 877 patients with UC (median age 36 years (range: 18-84), 45.8% female). At diagnosis, 39.2% presented with proctitis, 24.7% left-sided colitis and 36.0% extensive colitis. At the 1-year follow-up, 13.9% experienced disease progression, and 14.5% had received one or more biologic therapies. The colectomy rate was 0.9%. Steroid-free clinical remission was observed in 76.6%, and steroid-free endoscopic remission in 68.7%. Anaemia and initiation of systemic steroid treatment at diagnosis were associated with biologic therapy within the first year after diagnosis. CONCLUSION: In this population-based inception cohort, colectomy rate in the first year after diagnosis was low, and a high proportion of patients were in remission at 1-year follow-up. The use of biologic therapy increases, consistent with findings from previous studies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Strande V, Lund C, Hagen M, et al. Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort. Aliment Pharmacol Ther. 2024. PMID: 38837289. doi:10.1111/apt.18097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。